Corresponding Author: Silje Watterdal Syversen, MD, PhD, Division of Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, N-0319 Oslo, Norway (s.w.syversen@gmail.com).
Accepted for Publication: March 4, 2021.
Author Contributions: Drs Syversen and Sexton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Syversen, Goll, and Jørgensen contributed equally and are co–first authors. Drs Jahnsen, Bolstad, and Haavardsholm contributed equally and are co–last authors.
Concept and design: Syversen, Goll, Jørgensen, Olsen, Torp, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Acquisition, analysis, or interpretation of data: Syversen, Goll, Sandanger, Sexton, Olsen, Gehin, Warren, Brun, Klaasen, Karlsen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Blomgren, Bragnes, Dotterud, Thune, Ystrøm, Torp, Mielnik, Kvien, Jahnsen, Bolstad, Haavardsholm.
Drafting of the manuscript: Syversen, Goll, Jørgensen, Sexton, Warren, Blomgren, Torp, Kvien, Bolstad.
Critical revision of the manuscript for important intellectual content: Syversen, Goll, Jørgensen, Sandanger, Sexton, Olsen, Gehin, Warren, Brun, Klaasen, Karlsen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Bragnes, Dotterud, Thune, Ystrøm, Torp, Mielnik, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Statistical analysis: Syversen, Sexton, Olsen, Brun, Torp, Kvien, Haavardsholm.
Obtained funding: Syversen, Goll, Jørgensen, Torp, Kvien, Bolstad, Haavardsholm.
Administrative, technical, or material support: Syversen, Goll, Sandanger, Sexton, Gehin, Warren, Brun, Klaasen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Bragnes, Dotterud, Thune, Torp, Jahnsen, Bolstad, Haavardsholm.
Supervision: Syversen, Goll, Jørgensen, Michelsen, Ystrøm, Torp, Mørk, Kvien, Jahnsen, Haavardsholm.
Conflict of Interest Disclosures: Dr Syversen reported receipt of personal fees from Thermo Fisher. Dr Goll reported receipt of personal fees from Pfizer, AbbVie, Boehringer Ingelheim, Roche, Orion Pharma, Sandoz, and Novartis. Dr Jørgensen reported receipt of personal fees from Celltrion, AOP Orphan Pharmaceuticals, and Norgine. Dr Gehin reported receipt of personal fees from Roche. Dr Michelsen reported receipt of personal fees from Novartis and grants from Novartis (paid to employer). Dr Dotterud reported receipt of personal fees from LEO Pharma. Dr Mørk reported receipt of personal fees from Novartis Norge, LEO Pharma, ACO Hud Norge, Celgene, AbbVie, Galderma Nordic, and UCB. Dr Kvien reported receipt of grants from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and UCB and personal fees from AbbVie, Merck Sharp & Dohme, Hospira/Pfizer, Roche, UCB, Lilly, Hikma, Orion, Sanofi, Celltrion, Sandoz, Biogen, Amgen, Egis, Ewopharma, Mylan, EVA Pharma, and Gilead. Dr Bolstad reported receipt of personal fees from Roche, Janssen, and Novartis. Dr Haavardsholm reported receipt of personal fees from Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Lilly, and UCB. No other disclosures were reported.
Funding/Support: The study was funded by grants from the Norwegian Regional Health Authorities (interregional KLINBEFORSK grants) and the South-Eastern Norway Regional Health Authorities. The sponsor of the study was Diakonhjemmet Hospital.
Role of the Funder/Sponsor: Neither the funder of the study (the Regional Health Authorities) nor the sponsor (Diakonhjemmet Hospital) had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Neither the funder nor the sponsor had any right to veto publication or to control the decision regarding to which journal the manuscript was submitted. All drafts of the manuscript were prepared by the authors. All authors approved the final submitted version.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We acknowledge the patient representatives, Jon Hagfors (Norwegian Rheumatism Association), Bjørn Gulbrandsen (Norwegian IBD Patient Organization), and Hilde Mellum (Psoriasis and Eczema Association of Norway), for their contributions during planning and conduct of the study. We acknowledge the members of the scientific advisory board, Josef Smolen, MD, PhD (University of Vienna), Alejandro C. Balsa, MD, PhD (University Hospital La Paz, Madrid), Geert D’Haens, MD, PhD (Amsterdam Academic Medical Center), Jørn Brynskov, MD, PhD (University of Copenhagen Herlev Hospital), Knut E. A. Lundin, MD, PhD (University of Oslo), and Diamant Thaci, MD, PhD (University of Lubeck). No compensation was received for their contributions to the protocol. We acknowledge Cecilie Moe, Bjørn Solvang, Nina Flatner, Trond Smedsrud, and Marius Eid, Department of Research Support for Clinical Trials at Oslo University Hospital, and Anja Bye, Clinical Research Unit Central Norway, for research support and data management (received compensation for their work).